Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | iwCLL 2019 – facilitating the development of novel agents and treatment outcomes

Mary Ann Anderson • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Mary Ann Anderson, MBBS, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, talks about what she’s looking forward to at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Mary Ann Anderson

2:32
Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
Mary Ann Anderson • 8 Sep 2023
0:49
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax
Mary Ann Anderson • 8 Sep 2023
2:30
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies
Mary Ann Anderson • 8 Sep 2023
3:37
Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition
Mary Ann Anderson • 20 Sep 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals